Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a CE request form, statements of credit for physicians will be issued via email within 30 business days.


  • Review current status of checkpoint inhibitor use in urothelial bladder cancer at various stages of disease presentation and progression.
  • Explore the role of sequential therapy and multimodal and/or combination regimens involving checkpoint inhibitors.
  • Anticipate and appropriately manage adverse events that may occur in the use of checkpoint inhibitors in the patient with bladder cancer.

Target Audience

This activity is designed to meet the educational needs of urologists and urologic oncologists attending the 114th AUA Annual Meeting who diagnose and manage urothelial cancer.

Faculty Disclosure

All planners, speakers, authors, and reviewers involved with content development for continuing education activities provided by Creative Educational Concepts, Inc. are expected to disclose any real or perceived conflict of interest related to the content of the activity. Detailed disclosures will be included in participant materials or given prior to the start of the activity.